View Older Stories View More Recent Stories
-
Roth Capital Cuts Price Target on Depomed (DEPO) as Horizon Pharma (HZNP) Trades Down
-
Roth Capital Raises Price Target on Ligand Pharma (LGND) Ahead of 3Q Results
-
Roth Capital Starts MaxLinear (MXL) at Buy
-
Roth Capital Cuts Price Target on Zosano Pharma (ZSAN) Following Announced Discontinuance of ZP-PTH Agreement
-
Roth Capital Re-Starts Cosi Inc. (COSI) at Buy
-
Roth Capital Boosts FY16 Ests on Ballard Power (BLDP) Following Wins in China; Affirms at 'Buy'
-
Roth Capital Starts Inuvo (INUV) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 9/28: (BID) (GALE) (AAPL) (QSR)
-
Roth Capital Reiterates Buy on Rexahn Pharma (RNN) as Data Flows Begin
-
Rexahn Pharma (RNN) Starts Data Flow on RX-5902, RX-3117; Roth Capital Affirms at 'Buy'
-
Roth Affirms Galena Biopharma (GALE) at 'Buy' Fllowing GALE-301 Phase 2a Update; 1000 mcg Seen as Optimal
-
Roth Capital Downgrades Verastem (VSTM) to Neutral
-
Roth Capital Raised Price Target on VBL Therapeutics (VBLT) Following ASCO Showing
-
Roth Capital Reiterates Buy on Motorcar Parts of America (MPAA) After Visiting Headquarters
-
Roth Capital Upgrades ANI Pharmaceuticals (ANIP) to Buy
-
Pioneer Power (PPSI) Prices 1.125M Common Share Offering at $4
-
Pioneer Prices Underwritten Public Offering of Common Stock
-
Major Overhang for ImmunoCellular (IMUC) Removed with CIRM Grant - Roth Capital
-
Roth Capital Reiterates Buy on GigOptix (GIG) Following Terasquare Acquisition
-
Conatus Pharmaceuticals (CNAT) Bullish Stance Reiterated at Roth Capital Following Data
-
ESSA Pharma (EPIX) Bullish View Reiterated at Roth Capital Following IND Okay
-
Roth Affirms Neogen (NEOG) at 'Buy'; Developing Market Efforts Should Outpace FX Issues
-
Roth Positive on Motorcar Parts of America (MPAA) Following AutoZone's (AZO) Q4 Results
-
Roth Capital Raises Price Target on Concert Pharma (CNCE) Following CTP-656 Data
-
Roth Capital Raised Price Target on AcelRx Pharma (ACRX) Following Announced Monetization Agreement
-
Roth Capital Reiterates Buy on Cherokee (CHKE) Following U.K. Store Tours
-
Strongbridge Biopharma plc Announces Launch of Its Proposed Initial U.S. Public Offering
-
Strongbridge Biopharma (SBBP) Sees IPO Offering Size of 4.25M Shares
-
Roth Capital Reiterates Buy on Sky Solar Holdings (SKYS) Following Announced Partnership with Hudson Clean Energy Partners
-
Early Read on unique BV (QURE) Sanfilippo B Trial 'Encouraging', Roth Capital Says
-
Pioneer Announces Proposed Public Offering of Common Stock
-
Roth Capital Reiterates Buy on Daqo New Energy (DQ) Following Investor Meetings
-
Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares
-
Sun Basket Announces $4.5 Million In Venture Funding Led by PivotNorth Capital and Baseline Ventures
-
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Ublituximab Combo SPA Validates Study Design
-
Roth Capital Affirms Lion Bio (LBIO) at 'Buy' Following Positive TIL Phase 2 Data in Metastatic Melanoma
-
Notable 52-Week Highs and Lows 9/16: (ITCI) (COLL) (UA) High; (GBSN) (XNPT) (NR) Low
-
Roth Capital Downgrades Adept Technology (ADEP) to Neutral Amid Takeover
-
Great Basin Announces Retention of Roth Capital Partners as Financial Advisor in Restructuring of the Company’s Series C Warrants
-
Roth Capital Recommends Buying bluebird bio (BLUE) Into ASH
-
The Sheckler Foundation's 8th Annual Celebrity Golf Tournament Raised $300,000 to Empower Those in Need
-
Roth Capital Raises Price Target on Quicklogic Corp (QUIK) on Continuing Design Win Momentum
-
Roth Keeps Cytori Therapeutics (CYTX) at 'Buy' Following Scleradec-I Trial Results; Data Bodes Well for Pivotal Program
-
Roth Capital Reiterates Buy on Nektar Therapeutics (NKTR) After Meeting with Management
-
Roth Reaffirms Applied Genetic (AGTC) at 'Buy' Following FY15 Results; Fundamental Thesis Remains Unchanged
-
Roth Capital Starts Intec Pharma Ltd. (NTEC) at Buy
-
GigOptix, Inc. Closes Public Offering of Common Stock to Support Enhanced Strategic Growth Through Acquisitions
-
Roth Affirms Power Solutions (PSIX) at 'Buy' as Shares Retake Key Multiple Level
-
Roth Capital Cuts Price Target on PriceSmart (PSMT) As Comps Hold in High-Single-Digits
-
Roth Capital Reiterates Buy on Aduro Biotech (ADRO) Following Announced Incyte (INCY) Collaboration

